We analyzed the survival analysis of two groups of meningioma patients with EZH2 positive and negative, and we found that there was a statistically significant difference in the RFS, demonstrating that expression of EZH2 was associated with poorer RFS in meningioma [Mean RFS 48.9 (95% CI 35.9−62.0) months vs. 102.1 (95% CI 94.1−110.1) months, P < 0.001, Figure 2D]. The gene discussed is EZH2; the disease is meningioma.